CN114686005A - Blend of collagen and levorotatory polylactic acid - Google Patents
Blend of collagen and levorotatory polylactic acid Download PDFInfo
- Publication number
- CN114686005A CN114686005A CN202210348266.XA CN202210348266A CN114686005A CN 114686005 A CN114686005 A CN 114686005A CN 202210348266 A CN202210348266 A CN 202210348266A CN 114686005 A CN114686005 A CN 114686005A
- Authority
- CN
- China
- Prior art keywords
- parts
- collagen
- polylactic acid
- blend
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920000747 poly(lactic acid) Polymers 0.000 title claims abstract description 52
- 239000004626 polylactic acid Substances 0.000 title claims abstract description 52
- 102000008186 Collagen Human genes 0.000 title claims abstract description 45
- 108010035532 Collagen Proteins 0.000 title claims abstract description 45
- 229920001436 collagen Polymers 0.000 title claims abstract description 45
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- -1 lipid carotenoid Chemical class 0.000 claims abstract description 16
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims abstract description 14
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 14
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims abstract description 14
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims abstract description 14
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims abstract description 14
- 229930012538 Paclitaxel Natural products 0.000 claims abstract description 14
- 235000010208 anthocyanin Nutrition 0.000 claims abstract description 14
- 239000004410 anthocyanin Substances 0.000 claims abstract description 14
- 229930002877 anthocyanin Natural products 0.000 claims abstract description 14
- 150000004636 anthocyanins Chemical class 0.000 claims abstract description 14
- 235000021466 carotenoid Nutrition 0.000 claims abstract description 14
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims abstract description 14
- 235000005487 catechin Nutrition 0.000 claims abstract description 14
- 229950001002 cianidanol Drugs 0.000 claims abstract description 14
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 14
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 14
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims abstract description 14
- 235000012661 lycopene Nutrition 0.000 claims abstract description 14
- 239000001751 lycopene Substances 0.000 claims abstract description 14
- 229960004999 lycopene Drugs 0.000 claims abstract description 14
- 229960001592 paclitaxel Drugs 0.000 claims abstract description 14
- 239000008347 soybean phospholipid Substances 0.000 claims abstract description 14
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract description 14
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims abstract description 14
- 229920001285 xanthan gum Polymers 0.000 claims abstract description 14
- 239000000230 xanthan gum Substances 0.000 claims abstract description 14
- 229940082509 xanthan gum Drugs 0.000 claims abstract description 14
- 235000010493 xanthan gum Nutrition 0.000 claims abstract description 14
- YFZSQPRYLBGYKE-UHFFFAOYSA-N Jaceoside Natural products C1=C(O)C(OC)=CC(C=2OC3=CC(OC4C(C(O)C(O)C(CO)O4)O)=C(OC)C(O)=C3C(=O)C=2)=C1 YFZSQPRYLBGYKE-UHFFFAOYSA-N 0.000 claims abstract description 11
- GLAAQZFBFGEBPS-UHFFFAOYSA-N jaceosidin Chemical compound C1=C(O)C(OC)=CC(C=2OC3=CC(O)=C(OC)C(O)=C3C(=O)C=2)=C1 GLAAQZFBFGEBPS-UHFFFAOYSA-N 0.000 claims abstract description 11
- AOAPCDXPLWGVGI-UHFFFAOYSA-N jaceosidin Natural products COc1c(O)cc2OC(=CC(=O)c2c1O)c3ccc(O)c(C)c3 AOAPCDXPLWGVGI-UHFFFAOYSA-N 0.000 claims abstract description 11
- XRHHDQSPFPQKMS-UHFFFAOYSA-N sudachitin Natural products C1=C(O)C(OC)=CC(C=2OC3=C(OC)C(O)=C(OC)C(O)=C3C(=O)C=2)=C1 XRHHDQSPFPQKMS-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229930182478 glucoside Natural products 0.000 claims description 7
- 150000008131 glucosides Chemical class 0.000 claims description 7
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 6
- 239000000787 lecithin Substances 0.000 claims description 6
- 229940067606 lecithin Drugs 0.000 claims description 6
- 235000010445 lecithin Nutrition 0.000 claims description 6
- 230000000694 effects Effects 0.000 abstract description 2
- 238000002156 mixing Methods 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- VEVZSMAEJFVWIL-UHFFFAOYSA-O cyanidin cation Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 VEVZSMAEJFVWIL-UHFFFAOYSA-O 0.000 description 6
- 235000007336 cyanidin Nutrition 0.000 description 3
- 230000007547 defect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002473 artificial blood Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L89/00—Compositions of proteins; Compositions of derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/85—Polyesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention provides a blend of collagen and levorotatory polylactic acid. Comprises the following components in parts by weight: 40-50 parts of collagen, 30-35 parts of levorotatory polylactic acid, 16-20 parts of hyaluronic acid, 8-10 parts of xanthan gum, 0.5-1 part of jaceosidin, 0.3-0.6 part of anthocyanin, 0.2-0.4 part of lycopene, 0.2-0.4 part of taxol, 0.2-0.6 part of catechin, 0.4-0.6 part of lipid carotenoid, 0.2-0.4 part of soybean phospholipid and 0.1-0.3 part of pheophytin. The invention abandons the conventional single-component scheme, adopts the blending of collagen and levorotatory polylactic acid, and introduces other components to form a compound scheme, thereby obtaining a brand-new composition formula. The blend not only obviously improves the biological performance, but also has good stability and is comprehensively superior to the single-component efficacy of collagen or levorotatory polylactic acid. The invention has reasonable formula, good technical effect and outstanding technical advantages.
Description
Technical Field
The invention relates to the technical field of medical cosmetology, in particular to a blend of collagen and levorotatory polylactic acid.
Background
Polylactic acid is also classified into dextrorotatory polylactic acid (PDLA), levorotatory polylactic acid (PLLA), racemic polylactic acid (PDLLA), and optically inactive polylactic acid (Meso-PLA) because lactic acid has an asymmetric carbon atom in its molecule and is optically active. PLLA is an important biodegradable high molecular material, and has the characteristics of no toxicity, no irritation, biodegradability, absorption, high strength, good plasticity and easy processing and forming. The degradation period is 2-12 months. PLLA has many uses, mainly used in the medical field of surgical suture, dentistry, ophthalmology, medicinal controlled release system, artificial skin, artificial blood vessel, bone and soft tissue defect part filler, bioabsorbable scaffold, etc.
Collagen is a biological macromolecule, a main component in the connective tissue of animals, and is also a functional protein with the largest content and the widest distribution in mammals, accounting for 25-30 percent of the total protein, and even reaching more than 80 percent of certain organisms. Collagen has good biocompatibility, biodegradability and bioactivity, and thus is widely used in the fields of food, medicine, tissue engineering, cosmetics, and the like. In the prior art, collagen and L-polylactic acid respectively have certain biological properties, but the overall efficacy of the collagen and the L-polylactic acid still needs to be improved.
Disclosure of Invention
The invention aims to provide a blend of collagen and levorotatory polylactic acid aiming at the technical defects of the prior art so as to solve the technical problem of low biological performance of a single-component preparation.
In order to achieve the technical purpose, the invention adopts the following technical scheme:
the blend of the collagen and the levorotatory polylactic acid comprises the following components in parts by weight: 40-50 parts of collagen, 30-35 parts of levorotatory polylactic acid, 16-20 parts of hyaluronic acid, 8-10 parts of xanthan gum, 0.5-1 part of jaceosidin, 0.3-0.6 part of anthocyanin, 0.2-0.4 part of lycopene, 0.2-0.4 part of taxol, 0.2-0.6 part of catechin, 0.4-0.6 part of lipid carotenoid, 0.2-0.4 part of soybean phospholipid and 0.1-0.3 part of pheophytin.
Preferably, the blend further comprises 0.2 to 0.4 parts by weight of lecithin.
Preferably, the blend also comprises 0.8-1 weight part of glyceroglycolipid.
Preferably, the blend also comprises 0.1 to 0.3 weight part of dithio-aminopropionic acid.
Preferably, the blend also comprises 0.2-0.4 weight part of glucoside.
Preferably, the blend consists of the following ingredients in parts by weight: 45 parts of collagen, 32 parts of L-polylactic acid, 18 parts of hyaluronic acid, 9 parts of xanthan gum, 0.8 part of jaceosidin, 0.5 part of anthocyanin, 0.3 part of lycopene, 0.3 part of taxol, 0.4 part of catechin, 0.5 part of lipid carotenoid, 0.3 part of soybean phospholipid and 0.2 part of pheophytin.
Preferably, the blend consists of the following ingredients in parts by weight: 45 parts of collagen, 32 parts of levorotatory polylactic acid, 18 parts of hyaluronic acid, 9 parts of xanthan gum, 0.8 part of jaceosidin, 0.5 part of anthocyanin, 0.3 part of lycopene, 0.3 part of taxol, 0.4 part of catechin, 0.5 part of lipid carotenoid, 0.3 part of soybean phospholipid, 0.2 part of pheophytin, 0.3 part of lecithin, 0.9 part of glyceroglycolipid, 0.2 part of dithio-amino propionic acid and 0.3 part of glucoside.
The invention provides a blend of collagen and levorotatory polylactic acid. The technical scheme abandons the conventional single-component scheme, adopts the blending of collagen and L-polylactic acid, and introduces other components to form a compounding scheme, thereby obtaining a brand-new composition formula. The blend not only obviously improves the biological performance, but also has good stability and is comprehensively superior to the single-component efficacy of collagen or levorotatory polylactic acid. The invention has reasonable formula, good technical effect and outstanding technical advantages.
Detailed Description
Hereinafter, specific embodiments of the present invention will be described in detail. Well-known structures or functions may not be shown in detail in the following embodiments in order to avoid unnecessarily obscuring the details. Approximating language, as used herein in the following examples, may be applied to identify quantitative representations that could permissibly vary in number without resulting in a change in the basic function. Unless defined otherwise, technical and scientific terms used in the following examples have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
Example 1
A blend of collagen and levorotatory polylactic acid comprises the following components in parts by weight: 45 parts of collagen, 32 parts of L-polylactic acid, 18 parts of hyaluronic acid, 9 parts of xanthan gum, 0.8 part of jaceosidin, 0.5 part of anthocyanin, 0.3 part of lycopene, 0.3 part of taxol, 0.4 part of catechin, 0.5 part of lipid carotenoid, 0.3 part of soybean phospholipid and 0.2 part of pheophytin.
Example 2
A blend of collagen and levorotatory polylactic acid comprises the following components in parts by weight: 45 parts of collagen, 32 parts of levorotatory polylactic acid, 18 parts of hyaluronic acid, 9 parts of xanthan gum, 0.8 part of jaceosidin, 0.5 part of anthocyanin, 0.3 part of lycopene, 0.3 part of taxol, 0.4 part of catechin, 0.5 part of lipid carotenoid, 0.3 part of soybean phospholipid, 0.2 part of pheophytin, 0.3 part of lecithin, 0.9 part of glyceroglycolipid, 0.2 part of dithio-amino propionic acid and 0.3 part of glucoside.
Example 3
A blend of collagen and levorotatory polylactic acid comprises the following components in parts by weight: 40 parts of collagen, 30 parts of L-polylactic acid, 16 parts of hyaluronic acid, 8 parts of xanthan gum, 0.5 part of jaceosidin, 0.3 part of anthocyanin, 0.2 part of lycopene, 0.2 part of taxol, 0.2 part of catechin, 0.4 part of lipid carotenoid, 0.2 part of soybean phospholipid and 0.1 part of pheophytin.
Example 4
A blend of collagen and levorotatory polylactic acid comprises the following components in parts by weight: 50 parts of collagen, 35 parts of L-polylactic acid, 20 parts of hyaluronic acid, 10 parts of xanthan gum, 1 part of jaceosidin, 0.6 part of anthocyanin, 0.4 part of lycopene, 0.4 part of taxol, 0.6 part of catechin, 0.6 part of lipid carotenoid, 0.4 part of soybean phospholipid and 0.3 part of pheophytin.
Example 5
A blend of collagen and levorotatory polylactic acid comprises the following components in parts by weight: 45 parts of collagen, 32 parts of L-polylactic acid, 18 parts of hyaluronic acid, 9 parts of xanthan gum, 0.8 part of brown cyanidin, 0.5 part of anthocyanin, 0.3 part of lycopene, 0.3 part of taxol, 0.4 part of catechin, 0.5 part of lipid carotenoid, 0.3 part of soybean phospholipid, 0.2 part of pheophytin, 0.2 part of lecithin and 0.4 part of glucoside.
Example 6
A blend of collagen and levorotatory polylactic acid comprises the following components in parts by weight: a blend of collagen and levorotatory polylactic acid comprises the following components in parts by weight: 45 parts of collagen, 32 parts of L-polylactic acid, 18 parts of hyaluronic acid, 9 parts of xanthan gum, 0.8 part of brown cyanidin, 0.5 part of anthocyanin, 0.3 part of lycopene, 0.3 part of taxol, 0.4 part of catechin, 0.5 part of lipid carotenoid, 0.3 part of soybean phospholipid, 0.2 part of pheophytin, 0.9 part of glyceroglycolipid and 0.3 part of dithio-amino propionic acid.
Example 7
A blend of collagen and levorotatory polylactic acid comprises the following components in parts by weight: a blend of collagen and levorotatory polylactic acid comprises the following components in parts by weight: 45 parts of collagen, 32 parts of L-polylactic acid, 18 parts of hyaluronic acid, 9 parts of xanthan gum, 0.8 part of brown cyanidin, 0.5 part of anthocyanin, 0.3 part of lycopene, 0.3 part of taxol, 0.4 part of catechin, 0.5 part of lipid carotenoid, 0.3 part of soybean phospholipid, 0.2 part of pheophytin and 0.3 part of glucoside.
The embodiments of the present invention have been described in detail, but the description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention. Any modification, equivalent replacement, and improvement made within the scope of the application of the present invention should be included in the protection scope of the present invention.
Claims (7)
1. The blend of the collagen and the levorotatory polylactic acid is characterized by comprising the following components in parts by weight: 40-50 parts of collagen, 30-35 parts of levorotatory polylactic acid, 16-20 parts of hyaluronic acid, 8-10 parts of xanthan gum, 0.5-1 part of jaceosidin, 0.3-0.6 part of anthocyanin, 0.2-0.4 part of lycopene, 0.2-0.4 part of taxol, 0.2-0.6 part of catechin, 0.4-0.6 part of lipid carotenoid, 0.2-0.4 part of soybean phospholipid and 0.1-0.3 part of pheophytin.
2. The blend of collagen and L-polylactic acid according to claim 1, further comprising 0.2-0.4 weight part of lecithin.
3. The blend of collagen and L-polylactic acid according to claim 1, further comprising 0.8-1 weight part of glyceroglycolipid.
4. The blend of collagen and L-polylactic acid according to claim 1, further comprising 0.1-0.3 weight part of dithio amino propionic acid.
5. The blend of collagen and L-polylactic acid according to claim 1, further comprising 0.2-0.4 weight parts of glucoside.
6. The blend of collagen and L-polylactic acid according to claim 1, which is prepared from the following components in parts by weight: 45 parts of collagen, 32 parts of L-polylactic acid, 18 parts of hyaluronic acid, 9 parts of xanthan gum, 0.8 part of jaceosidin, 0.5 part of anthocyanin, 0.3 part of lycopene, 0.3 part of taxol, 0.4 part of catechin, 0.5 part of lipid carotenoid, 0.3 part of soybean phospholipid and 0.2 part of pheophytin.
7. The blend of collagen and L-polylactic acid according to claim 1, which is prepared from the following components in parts by weight: 45 parts of collagen, 32 parts of levorotatory polylactic acid, 18 parts of hyaluronic acid, 9 parts of xanthan gum, 0.8 part of jaceosidin, 0.5 part of anthocyanin, 0.3 part of lycopene, 0.3 part of taxol, 0.4 part of catechin, 0.5 part of lipid carotenoid, 0.3 part of soybean phospholipid, 0.2 part of pheophytin, 0.3 part of lecithin, 0.9 part of glyceroglycolipid, 0.2 part of dithio-amino propionic acid and 0.3 part of glucoside.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210348266.XA CN114686005A (en) | 2022-04-01 | 2022-04-01 | Blend of collagen and levorotatory polylactic acid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210348266.XA CN114686005A (en) | 2022-04-01 | 2022-04-01 | Blend of collagen and levorotatory polylactic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114686005A true CN114686005A (en) | 2022-07-01 |
Family
ID=82141489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210348266.XA Pending CN114686005A (en) | 2022-04-01 | 2022-04-01 | Blend of collagen and levorotatory polylactic acid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114686005A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115887760A (en) * | 2022-11-21 | 2023-04-04 | 娜罗曼苏(杭州)医疗生物科技有限公司 | Preparation process of L-polylactic acid for injection |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104258470A (en) * | 2014-05-13 | 2015-01-07 | 山东省医疗器械研究所 | Mixed gel of polylactic acid microspheres and cross-linked hyaluronic acid for injection and preparation method of mixed gel |
| CN105233332A (en) * | 2015-09-30 | 2016-01-13 | 苏州蔻美新材料有限公司 | Polylactic acid-polyvinyl alcohol absorbable surgical suture and preparation method thereof |
| CN109331224A (en) * | 2018-09-21 | 2019-02-15 | 陈炯锋 | A kind of gel and its preparation method and application |
| CN111110623A (en) * | 2019-06-28 | 2020-05-08 | 青岛华澳现代医疗美容有限公司 | Self-repairing small needle nutrient solution formula |
| CN113413330A (en) * | 2021-06-29 | 2021-09-21 | 玉本妍(南京)医疗科技有限公司 | Compounding method and compounding preparation of collagen and levorotatory polylactic acid |
-
2022
- 2022-04-01 CN CN202210348266.XA patent/CN114686005A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104258470A (en) * | 2014-05-13 | 2015-01-07 | 山东省医疗器械研究所 | Mixed gel of polylactic acid microspheres and cross-linked hyaluronic acid for injection and preparation method of mixed gel |
| CN105233332A (en) * | 2015-09-30 | 2016-01-13 | 苏州蔻美新材料有限公司 | Polylactic acid-polyvinyl alcohol absorbable surgical suture and preparation method thereof |
| CN109331224A (en) * | 2018-09-21 | 2019-02-15 | 陈炯锋 | A kind of gel and its preparation method and application |
| CN111110623A (en) * | 2019-06-28 | 2020-05-08 | 青岛华澳现代医疗美容有限公司 | Self-repairing small needle nutrient solution formula |
| CN113413330A (en) * | 2021-06-29 | 2021-09-21 | 玉本妍(南京)医疗科技有限公司 | Compounding method and compounding preparation of collagen and levorotatory polylactic acid |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115887760A (en) * | 2022-11-21 | 2023-04-04 | 娜罗曼苏(杭州)医疗生物科技有限公司 | Preparation process of L-polylactic acid for injection |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10335512B2 (en) | Dermal filler based on crosslinked hyaluronic acid and carboxymethyl cellulose lubricant | |
| US10064889B2 (en) | Mercapto-modified biocompatible macromolecule derivatives with low degree of mercapto-modification and the cross-linked materials and uses thereof | |
| DE69630990T2 (en) | Bio-contractual adhesive | |
| RU2683286C2 (en) | Method for crosslift of hyaluronic acid, method for preparation of injection hydrogel, hydrogel and use thereof | |
| Yang et al. | A bioinspired gallol-functionalized collagen as wet-tissue adhesive for biomedical applications | |
| DE69231421T2 (en) | FIBRINE OR FIBRINOGEN AND BIODEGRADABLE AND BIOCOMPATIBLE POLYMERS CONTAINING COMPOSITION FOR TISSUE TREATMENT | |
| KR101918452B1 (en) | Composition having Carboxymethyl Chitosan, cross-linked hyaluronic acid and collagen and, manufacturing methods for the same | |
| EP2932989B1 (en) | Tissue sealant in which collagen and fibrin are mixed, and method for preparing same | |
| EP1888054B1 (en) | Antimicrobial composition | |
| FR2994846A1 (en) | COMPOSITION, STERILIZED, COMPRISING AT LEAST ONE HYALURONIC ACID AND MAGNESIUM ASCORBYL PHOSPHATE | |
| BR0306846A (en) | Blood substitute product, composition useful as a blood substitute, method for making a blood substitute product, and method of using a blood substitute product to deliver oxygen to a tissue. | |
| US10272181B2 (en) | Method for obtaining an injectable hydrogel based on hyaluronic acid containing lidocaine and an alkaline agent, sterilized with heat | |
| JPH01265970A (en) | Collagen water solution or water dispersion solution including hyaluronic acid | |
| AU2005302497A1 (en) | Bioabsorbable polymers comprising calcium carbonate | |
| Liu | Fabrication and evaluation of a biodegradable proanthocyanidin‐crosslinked gelatin conduit in peripheral nerve repair | |
| CN114686005A (en) | Blend of collagen and levorotatory polylactic acid | |
| Peng et al. | ‐stimulated crosslinking of catechol‐conjugated hydroxyethyl chitosan as a tissue adhesive | |
| Martins et al. | Biocompatibility analysis of chemomechanical caries removal material Papacarie on cultured fibroblasts and subcutaneous tissue | |
| CN114452436B (en) | Collagen-based injectable self-repairing hydrogel and preparation method thereof | |
| EP2977460B1 (en) | Preparation method for hyaluronic acid, and anti-adhesive composition comprising hyaluronic acid prepared by same preparation method | |
| JP2020058786A (en) | Biomaterial devices and topical compositions for guided tissue regeneration | |
| JP2020058785A (en) | Biomaterial devices and topical compositions for treatment of skin abnormalities | |
| KR20230119104A (en) | Silk-hyaluronic acid composition for tissue filling, tissue spacing, and tissue bulking | |
| EP2185207B1 (en) | Combination for an adhesive bonding of biological tissues | |
| US20200023042A1 (en) | Composition for wound healing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220701 |
|
| RJ01 | Rejection of invention patent application after publication |